Recursion Pharmaceuticals (RXRX) Operating Margin (2020 - 2026)
Recursion Pharmaceuticals posted quarterly Operating Margin of 1985.55% for Q1 2026, down 68770.0% year-on-year from N/an in Q1 2025, and down 551.34% on a QoQ basis from 304.84% in Q4 2025.
Recursion Pharmaceuticals (RXRX) has 7 years of Operating Margin data on file, last reported at 1985.55% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 68770.0% year-over-year to 1985.55%; the trailing twelve-month figure through Mar 2026 stood at 881.32% (up 7876.0% YoY), and the FY2025 full-year result was 867.87%, down 5377.0% from the prior year.
- Operating Margin for Q1 2026 stood at 1985.55%, down from 304.84% in the prior quarter.
- Across five years, Operating Margin topped out at 304.84% in Q4 2025 and bottomed at 4042.41% in Q4 2024.
- The 5-year median for Operating Margin is 862.54% (2022), against an average of 1156.03%.
- The widest annual swing landed in 2024, when Operating Margin tumbled 313405 bps; it then soared 373757 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 445.91% in 2022, then slumped by 104 bps to 908.36% in 2023, then sank by 345 bps to 4042.41% in 2024, then surged by 92 bps to 304.84% in 2025, then sank by 551 bps to 1985.55% in 2026.
- The last three Operating Margin figures came in at 1985.55% (Q1 2026), 304.84% (Q4 2025), and 3327.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Recursion Pharmaceuticals | 1.90 Bn | 1.24 Bn | -6.02 Mn | -1,985.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,985.55% |
| Dec 31, 2025 | -304.84% |
| Sep 30, 2025 | -3,327.57% |
| Jun 30, 2025 | -916.75% |
| Mar 31, 2025 | -1,297.85% |
| Dec 31, 2024 | -4,042.41% |
| Sep 30, 2024 | -377.10% |
| Jun 30, 2024 | -697.39% |
| Mar 31, 2024 | -698.42% |
| Dec 31, 2023 | -908.36% |
| Sep 30, 2023 | -945.12% |
| Jun 30, 2023 | -741.72% |
| Mar 31, 2023 | -575.78% |
| Dec 31, 2022 | -445.91% |
| Sep 30, 2022 | -475.48% |
| Jun 30, 2022 | -862.54% |
| Mar 31, 2022 | -1,049.71% |
| Dec 31, 2021 | -2,564.55% |
| Sep 30, 2021 | -1,831.18% |
| Jun 30, 2021 | -1,605.69% |
| Mar 31, 2021 | -1,189.85% |
| Dec 31, 2020 | -950.61% |
| Sep 30, 2020 | -2,192.59% |
| Jun 30, 2020 | -9,794.09% |
| Mar 31, 2020 | -30,571.67% |